- Home
- SEED vs MIRA Comparison
SEED vs MIRA Comparison
Compare SEED & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- MIRA
- Stock Information
- Founded
- SEED 1997
- MIRA 2020
- Country
- SEED China
- MIRA United States
- Employees
- SEED N/A
- MIRA N/A
- Industry
- SEED Farming/Seeds/Milling
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- MIRA Health Care
- Exchange
- SEED Nasdaq
- MIRA Nasdaq
- Market Cap
- SEED 16.1M
- MIRA 18.4M
- IPO Year
- SEED N/A
- MIRA 2023
- Fundamental
- Price
- SEED $2.02
- MIRA $1.10
- Analyst Decision
- SEED
- MIRA Strong Buy
- Analyst Count
- SEED 0
- MIRA 2
- Target Price
- SEED N/A
- MIRA $14.00
- AVG Volume (30 Days)
- SEED 128.0K
- MIRA 226.5K
- Earning Date
- SEED 02-10-2025
- MIRA 03-31-2025
- Dividend Yield
- SEED N/A
- MIRA N/A
- EPS Growth
- SEED N/A
- MIRA N/A
- EPS
- SEED 0.46
- MIRA N/A
- Revenue
- SEED $16,163,803.00
- MIRA N/A
- Revenue This Year
- SEED N/A
- MIRA N/A
- Revenue Next Year
- SEED N/A
- MIRA N/A
- P/E Ratio
- SEED $4.43
- MIRA N/A
- Revenue Growth
- SEED 21.51
- MIRA N/A
- 52 Week Low
- SEED $1.64
- MIRA $0.51
- 52 Week High
- SEED $6.38
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- SEED 42.55
- MIRA 43.36
- Support Level
- SEED $2.08
- MIRA $1.09
- Resistance Level
- SEED $2.21
- MIRA $1.18
- Average True Range (ATR)
- SEED 0.21
- MIRA 0.06
- MACD
- SEED -0.03
- MIRA -0.00
- Stochastic Oscillator
- SEED 12.82
- MIRA 7.69
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.